Kimberli Brill has over 20 years of clinical development experience across all phases of oncology trials. She has worked on both targeted therapies and immunotherapies for solid and hematologic malignancies. Over the course of her career, she has worked for large pharmaceutical companies and small biotechs, including Imclone, GSK, Incyte, Array Biopharma, Pfizer, and most recently at Prelude Therapeutics. Kimberli has contributed to the development of several approved cancer therapies including cetuximab, lapatinib, ofatumumab, ruxolitinib, encorafenib, binimetinib and has made significant contributions to the development of numerous experimental targeted molecules and immune therapies. Kimberli has a proven track record of success in the design and execution of oncology clinical trials. Since earning her Bachelor of Science degree in nursing, she has been committed to improving patient outcomes and advancing the field of oncology drug development.